Vol. 150, No. 13 — March 26, 2016

GOVERNMENT NOTICES

DEPARTMENT OF HEALTH

DEPARTMENT OF HEALTH ACT

Notice of annual increase of Health Canada’s Drug Master Files and Certificate of a Pharmaceutical Product fees

Notice is hereby given that the Minister of Health, under the Ministerial Authority to Enter into Contract, hereby updates the fees that are payable for the provision of Drug Master Files and Certificate of a Pharmaceutical Product services by 2%, beginning April 1, 2016. These fees will continue to be updated annually, with an automatic 2% increase to align with the Drug Program’s regulatory user fees.

This change is effective beginning on April 1, 2016. The current fees and the fees updated as of April 1, 2016, are listed below.

Any inquiries or comments about the updated fees can be directed to Deryck Trehearne, Director General, Resource Management Operations Directorate, Health Products and Food Branch, 613-957-6690 (telephone), cri_irc_consultations@hc-sc.gc.ca (email).

Services Fee as of April 1, 2015 Fee as of April 1, 2016
Certificate of Pharmaceutical Product (or a supplemental copy of a Certificate of Pharmaceutical Product) $82 $84
Drug Master Files $424 $433
Drug Master Files — letter of access $191 $196
Drug Master Files — biannual updates $191 $196

[13-1-o]

DEPARTMENT OF HEALTH

FINANCIAL ADMINISTRATION ACT

Notice of annual increase of fees pursuant to the Fees in Respect of Drugs and Medical Devices Regulations

Notice is hereby given, under section 19.2 of the Financial Administration Act, that in keeping with section 4 of the 2011 Fees in Respect of Drugs and Medical Devices Regulations, every fee outlined by the Regulations is to be increased annually by 2%, rounded up to the nearest dollar.

The current fees and the fees updated as of April 1, 2016, are listed below.

Any inquiries or comments about the updated fees can be directed to Deryck Trehearne, Director General, Resource Management Operations Directorate, Health Products and Food Branch, 613-957-6690 (telephone), cri_irc_consultations@hc-sc.gc.ca (email).

Fee Category Section in Fees in Respect of Drugs and Medical Devices Regulations Fee as of April 1, 2015 Fee as of April 1, 2016
PART 2 — DRUGS
Fees For Examination Services — Schedule 1
New active substance 6 $328,498 $335,068
Clinical or non-clinical data and chemistry and manufacturing data 6 $166,383 $169,711
Clinical or non-clinical data only 6 $77,655 $79,209
Comparative studies 6 $46,937 $47,876
Chemistry and manufacturing data only 6 $22,192 $22,636
Published data only 6 $18,402 $18,771
Switch status from prescription drug to non-prescription drug 6 $44,685 $45,579
Labelling only 6 $2,990 $3,050
Administrative submission 6 $310 $317
Disinfectants 6 $4,137 $4,220
Drug identification number application — labelling standards 6 $1,658 $1,692
Remission
Remission processing fee 11(1)(a)(iii) $543 $554
Establishment Licence Fees
Fabrication of Drugs — Schedule 2
Basic fee 19(1), 27, 28(1)(a), 28(2)(a) $16,725 $17,060
Each additional category 19(1)(a) $4,191 $4,275
Dosage form classes 
  • 2 classes
19(1)(b) $8,369 $8,537
  • 3 classes
19(1)(b) $16,725 $17,060
  • 4 classes
19(1)(b) $20,916 $21,335
  • 5 classes
19(1)(b) $25,092 $25,594
  • 6 classes
19(1)(b) $29,270 $29,856
Each additional class 19(1)(b) $1,679 $1,713
Sterile dosage forms 19(1)(c) $8,369 $8,537
Packing/Labelling of Drugs — Schedule 3
Basic fee 20(1), 20(3)(a), 28(1)(b), 28(2)(b) $11,183 $11,407
Each additional category 20(1)(a) $2,794 $2,850
Dosage form classes 
  • 2 classes
20(1)(b) $5,577 $5,689
  • 3 or more classes
20(1)(b) $8,369 $8,537
Importation and Distribution of Drugs — Schedule 4
Basic fee 21(a), 22, 28(1)(c) and (d), 28(2)(c) and (d) $6,973 $7,113
Each additional category 21(a)(i), 22(a) $1,745 $1,780
Dosage form classes
  • 2 classes
21(a)(ii), 22(b) $3,488 $3,558
  • 3 or more classes
21(a)(ii), 22(b) $6,973 $7,113
Each fabricator 21(b)(i) $1,679 $1,713
Each additional dosage form class for each fabricator 21(b)(ii) $846 $863
Distribution or Wholesaling
Distribution or wholesaling fee 23 $4,191 $4,275
Testing
Testing fee 24 $2,794 $2,850
Drug Analysis — Schedule 5
Vaccines (1) 25 $27,874 $28,432
Drugs, not included in items 1, 6 and 9 of this Schedule, that are listed in Schedule D to the Food and Drugs Act 25 $11,151 $11,375
Drugs for human use that are prescription drugs, controlled drugs or narcotics 25 $8,369 $8,537
Drugs for human use, not included in any other item, for which a drug identification number has been assigned 25 $4,191 $4,275
Radiopharmaceuticals 25 $0 $0
Whole blood and its components (6) 25 $0 $0
Hemodialysis products 25 $0 $0
Drugs that are labelled as disinfectants, including those listed in paragraph 9(f) of this Schedule, but excluding other drugs labelled as disinfectants of medical devices 25 $0 $0
Drugs that meet the requirements of a class monograph having one of the following titles (9)
  • Acne therapies
25 $0 $0
  • Antidandruff products
25 $0 $0
  • Antiperspirants
25 $0 $0
  • Antiseptic skin cleaners
25 $0 $0
  • Athlete’s foot treatments
25 $0 $0
  • Contact lens disinfectants 9(f)
25 $0 $0
  • Fluoride-containing anti-caries products
25 $0 $0
  • Medicated skin care products
25 $0 $0
  • Sunburn protectants
25 $0 $0
  • Throat lozenges
25 $0 $0
Fees for the Examination of Dealer’s Licence Applications
Dealer’s Licence
Dealer’s licence 31(1) $4,884 $4,982
Fees for Right to Sell Drugs
Annual fee 35(1) $1,106 $1,129
PART 3 — MEDICAL DEVICE FEES
Fees for the Examination of Medical Device Licence Applications
Class II Medical Devices
Class II — Licence application 39(1) $381 $389
Class III Medical Devices — Schedule 6
Licence application 40(1)(a), 41(a) $5,469 $5,579
Licence application for a near patient in vitro diagnostic device 40(1)(a), 41(a) $9,310 $9,497
Change referred to in paragraph 34(a) of the Medical Devices Regulations that relates to manufacturing 40(1)(a), 41(a) $1,376 $1,404
Any other change referred to in paragraph 34(a) or (b) of the Medical Devices Regulations 40(1)(a), 41(a) $5,122 $5,225
Class IV Medical Devices — Schedule 7
Licence application 40(1)(b), 41(b) $12,720 $12,975
Licence application for devices that contain human or animal tissue 40(1)(b), 41(b) $11,866 $12,104
Licence application for a near patient in vitro diagnostic device 40(1)(b), 41(b) $21,683 $22,117
Change referred to in paragraph 34(a) of the Medical Devices Regulations that relates to manufacturing 40(1)(b), 41(b) $1,376 $1,404
Any other change referred to in paragraph 34(a) or (b) of the Medical Devices Regulations 40(1)(b), 41(b) $5,836 $5,953
Remission
Remission processing fee 44(1)(a)(iii) $57 $59
Fee for Right to Sell Licensed Class II, III or IV Medical Devices
Fee (if annual gross revenue of medical device sales is less than $20,000) 48(1)(a) $57 $59
Fee (in any other case) 48(1)(b) $359 $367
Fees for the Examination of an Application for an Establishment Licence
Medical devices establishment licence 51(1) $7,794 $7,950

[13-1-o]

DEPARTMENT OF HEALTH

HAZARDOUS MATERIALS INFORMATION REVIEW ACT

Decisions, undertakings and orders on claims for exemption

Pursuant to paragraph 18(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of the decisions of the screening officer respecting each claim for exemption and the relevant material safety data sheet (MSDS) and (where applicable) the label listed below.

In accordance with section 20 of the Hazardous Materials Information Review Act, a claimant or any affected party, as defined, may appeal a decision or order of a screening officer. An affected party may also appeal an undertaking in respect of which a notice has been published in the Canada Gazette. To initiate the appeal process, a Statement of Appeal (Form 1) as prescribed by the Hazardous Materials Information Review Act Appeal Board Procedures Regulations must be completed and delivered, along with the fee prescribed by section 12 of the Hazardous Materials Information Review Regulations, within 45 days of the publication of this notice in the Canada Gazette, Part I, to the Chief Appeals Officer at the following address: Workplace Hazardous Materials Bureau, 269 Laurier Avenue West, 4th Floor, Ottawa, Ontario K1A 0K9.

ROSSLYNN MILLER-LEE
Chief Screening Officer

On February 11, 2015, the Hazardous Products Act (HPA) was amended, and the Controlled Products Regulations (CPR) and the Ingredient Disclosure List were repealed and replaced with the new Hazardous Products Regulations (HPR). The revised legislation (HPA/HPR) is referred to as WHMIS 2015 and the former legislation (HPA/CPR) is referred to as WHMIS 1988.

Transitional provisions allow compliance with either WHMIS 1988 or WHMIS 2015 for a specified period of time. All claims for exemption in this publication were filed and evaluated in accordance with the provisions of WHMIS 1988.

There were no written representations from affected parties with respect to any of the claims for exemption and related MSDSs or labels mentioned below.

Each of the claims for exemption listed in the table below was found to be valid except for those for Registry Numbers (RNs) 9184, 9214, 9431, 9432, 9438, 9439, 9444, 9447, 9459, 9544, 9562, 9566, 9567 and 9578, which were found to be partially valid, and RNs 9477 and 9535, which were found to be invalid. The screening officer reached this decision after reviewing the information in support of the claim, having regard exclusively to the criteria found in section 3 of the Hazardous Materials Information Review Regulations.

Claimant Product Identifier RN Date of Decision
Allnex Canada Inc., (c/o Goodmans, LLP) EBECRYL® 811 radiation curing resins 9184 2015-10-06
The Lubrizol Corporation LUBRIZOL® PV1125 9187 2015-10-30
Ingevity Corp. INDULIN® 201 9191 2015-10-21
Nalco Canada ULC ASP® FFS200 9196 2015-11-27
Hexion Canada Inc. EPI-REZ Resin 6520-WH-53 9204 2015-11-14
W-TECH Technologies Ltd. ADDITIVE NCS 9214 2015-10-14
Afton Chemical Corporation HiTEC® 510 Performance Additive 9402 2015-07-09
Cytec Industries Inc. BR® 623-1 Potting Compound 9425 2015-11-17
The Lubrizol Corporation SLF8216 9431 2015-10-02
The Lubrizol Corporation ANGLAMOL® 6055 9432 2015-10-02
The Lubrizol Corporation SLF8218 9433 2015-10-27
Cytec Industries Inc. CYASORB® UV-3529 Light Stabilizer 9435 2015-10-30
Cytec Industries Inc. AERO® MAXGOLD® 900 Promoter 9436 2015-10-16
Nalco Canada ULC NALCO® FFR730 9437 2015-11-18
Nalco Canada ULC FFR760 9438 2015-11-18
Cytec Industries Inc. MELTBOND® 6726 Primer 9439 2015-10-22
Momentive Performance Materials Niax* silicone L-6915 9442 2015-10-30
Momentive Performance Materials Niax* silicone L-6895 9443 2015-10-30
Rohm and Haas Canada LP RINSEABLE PRIMER RP-1 9444 2015-12-15
Afton Chemical Corporation HiTEC® 6406 Fuel Additive 9445 2015-11-24
Afton Chemical Corporation ACTRACOR T 9446 2015-10-16
Afton Chemical Corporation POLARTECH PRIMA CLY 9447 2015-12-15
Afton Chemical Corporation ACTRAFOS® 110A Lubricant Additive 9449 2015-10-01
Afton Chemical Corporation Polartech PE 2111 9450 2015-10-01
The Lubrizol Corporation LUBRIZOL® 6312A 9453 2015-11-19
Afton Chemical Corporation ACTRASOL PSR 9458 2015-10-14
Momentive Performance Materials Niax* catalyst A-4 9459 2015-12-09
DuPont Electronic and Communication Technologies-MCM PE772 9460 2015-11-05
DuPont Electronic and Communication Technologies-MCM PE771 9461 2015-11-05
Momentive Performance Materials Niax* catalyst A-230 9464 2015-12-09
Momentive Performance Materials Niax* silicone L-595 9466 2015-10-30
DuPont Electronic and Communication Technologies-MCM PE872 9468 2015-10-09
Halliburton Energy Services, Inc. LOSURF-330 SURFACTANT 9470 2015-11-23
Momentive Performance Materials SPUR+ 1050 MM Prepolymer 9472 2015-10-19
Ingevity Corp. EVOTHERM® P15 9473 2015-11-27
LATICRETE International Inc. Stone Tech Semi-Gloss Finishing Sealer 9474 2015-11-20
LATICRETE International Inc. Semi-Gloss Sealer & Finish 9475 2015-11-20
Chemours Canada Company Particlear® - Ingredient A 9477 2015-12-21
Ingevity Corp. EnvaMul™ 1794 9478 2015-12-21
Ingevity Corp. EnvaMul™ 200 9479 2015-10-29
Ingevity Corp. EnvaMul™ 600 9480 2015-11-03
Ingevity Corp. EnvaMul™ 1772 9481 2015-11-18
Quadra Chemicals Ltd. DeltaSolv-2™ 9482 2015-11-24
Ingevity Corp. EnvaMul™ 1699 9483 2015-12-21
Cansolv Technologies Inc. CANSOLV™ Absorbent DS 9487 2015-10-23
Chemtrade Logistics Inc. Clar+Ion® A502P 9510 2015-12-09
Chemtrade Logistics Inc. Clar+Ion® A502.5P 9511 2015-12-09
Chemtrade Logistics Inc. Clar+Ion® A505P 9512 2015-12-09
Chemtrade Logistics Inc. Clar+Ion® A510P 9513 2015-12-09
Chemtrade Logistics Inc. Clar+Ion® A515P 9514 2015-12-09
Chemtrade Logistics Inc. Hyper+Ion® 705 9515 2015-12-09
Baker Hughes Canada Company SCW8234 SCALE INHIBITOR 9519 2015-11-25
Atotech Canada Ltd. EXPT ZINNI AL 454-1 9535 2015-12-21
Stepan Company AGENT 3796-95 9536 2015-11-25
Ingevity Corp. EVOTHERM® EH 9540 2015-10-09
The Lubrizol Corporation FIXATE™ SUPERHOLD POLYMER 9541 2015-10-09
The Lubrizol Corporation Lubrizol® 5782S 9544 2015-12-16
Baker Hughes Canada Company RE32501PAO PARAFFIN INHIBITOR 9545 2015-12-16
Calfrac Well Services Corp. DWP-958 9550 2015-12-16
Rohm and Haas Canada LP Monomer QM-1458 9554 2015-12-09
Rohm and Haas Canada LP Monomer QM-516 9555 2015-12-09
Ingevity Corp. INDULIN® AA-83 9559 2015-10-23
Nalco Canada ULC CORE SHELL® 71306 9561 2015-12-09
Afton Chemical Corporation HiTEC®8888Z Performance Additive 9562 2015-12-24
Akzo Nobel Surface Chemistry LLC REDICOTE® 82S-1 9566 2015-12-11
Akzo Nobel Surface Chemistry LLC REDISET® WMX-8017A 9567 2015-12-11
Akzo Nobel Surface Chemistry LLC REDICOTE® E-4819 9568 2015-12-11
Ingevity Corp. INDULIN® AA-81 9575 2015-11-27
Ingevity Corp. INDULIN® AA-89 9576 2015-12-09
Afton Chemical Corporation HiTEC® 5714 Performance Additive 9578 2015-12-22
Afton Chemical Corporation HiTEC® 521 Performance Additive 9579 2015-12-09
Afton Chemical Corporation HiTEC® 521G Performance Additive 9580 2015-12-09
Afton Chemical Corporation HiTEC® 543 Performance Additive 9581 2015-12-09
The Lubrizol Corporation ANGLAMOL® 33EM 9582 2015-12-09
Akzo Nobel Surface Chemistry LLC Redicote® E-4868 9585 2015-12-09
Allnex Canada Inc., (c/o Goodmans LLP) EBECRYL® 4265 radiation curing resins 9593 2015-12-10
Cytec Industries Inc. AERO® 5100 Promoter 9620 2015-12-21
Baker Hughes Canada Company RE32553 9662 2015-12-16

The subject of the claim on which the screening officer issued a decision for the following claims is different from the subject of the claim that was published in the Notice of Filing.

RN Notice of Filing Publication Date Original Subject of the Claim Revised Subject of the Claim
9184 2014-04-26 C.i. of one ingredient C.i. of two ingredients
9187 2014-04-26 C.i. of two ingredients C.i. and c. of two ingredients, c. of two ingredients
9196 2014-04-26 C.i. of one ingredient C.i. and c. of one ingredient, c. of three ingredients
9425 2015-04-25 C.i. of two ingredients C.i. and c. of one ingredient, c. of five ingredients
9431 2015-04-25 C.i. and c. of one ingredient C.i. and c. of three ingredients
9432 2015-04-25 C.i. and c. of one ingredient C.i. and c. of three ingredients
9433 2015-04-25 C.i. and c. of one ingredient C.i. and c. of one ingredient, c. of one ingredient
9437 2015-04-25 C.i. of one ingredient C.i. and c. of one ingredient, c. of one ingredient
9438 2015-04-25 C.i. of one ingredient C.i. and c. of one ingredient, c. of two ingredients
9442 2015-04-25 C.i. and c. of two ingredients C.i. and c. of two ingredients, c. of one ingredient
9443 2015-04-25 C.i. and c. of two ingredients C.i. and c. of two ingredients, c. of three ingredients
9445 2014-04-25 C.i. of two ingredients C.i. and c. of three ingredients, c. of one ingredient
9453 2015-07-25 C.i. and c. of two ingredients C.i. and c. of two ingredients, c. of one ingredient/ I.c. et c. de deux ingrédients, c. d’un ingrédient
9459 2015-07-25 C.i. of three ingredients/ I.c. de trois ingrédients C.i. and c. of three ingredients, c. of one ingredient
9460 2015-07-25 C.i. and c. of two ingredients C.i. and c. of two ingredients, c. of three ingredients
9461 2015-07-25 C.i. and c. of two ingredients C.i. and c. of two ingredients, c. of three ingredients
9464 2015-07-25 C.i. and c. of one ingredient C.i. and c. of one ingredient, c. of two ingredients
9466 2015-07-25 C.i. and c. of two ingredients C.i. and c. of two ingredients, c. of one ingredient
9470 2015-07-25 C.i. and c. of one ingredient C.i. and c. of three ingredients, c. of one ingredient
9474 2015-07-25 C.i. and c. of two ingredients C.i. and c. of two ingredients, c. of one ingredient
9475 2015-07-25 C.i. and c. of two ingredients C.i. and c. of two ingredients, c. of one ingredient
9478 2015-07-25 C.i. and c. of two ingredients C.i. and c. of two ingredients, c. of one ingredient
9483 2015-07-25 C.i. and c. of four ingredients C.i. and c. of four ingredients, c. of one ingredient
9550 2015-11-07 C.i. and c. of four ingredients C.i. and c. of four ingredients, c. of one ingredient
9561 2015-11-07 C.i. and c. of one ingredient, c. of one ingredient C.i. and c. of two ingredients, c. of one ingredient

Note: C.i. = Chemical identity and c. = concentration

Having regard for the various data readily available in the literature and any information provided by the claimant, the screening officer found that only the MSDSs in respect of the claims bearing RNs 9425, 9472, 9477, 9479, 9487, 9519, 9540, 9541, 9545, 9554, 9555, 9559, 9575, 9576, 9579, 9580, 9581, 9582, 9585, 9620, and 9662 complied with the requirements of the relevant legislation.

In all cases where the MSDS or the label was determined not to be in compliance with the relevant legislation, pursuant to subsection 16.1(1) of the Hazardous Materials Information Review Act, the claimant was given 30 days to provide the screening officer with a signed undertaking accompanied by the MSDS or the label amended as necessary.

CLAIMS FOR WHICH THE SCREENING OFFICER WAS SATISFIED THAT THE CLAIMANT HAD TAKEN THE MEASURES SET OUT IN THE UNDERTAKING

Pursuant to paragraph 18(1)(b) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that has been disclosed on the relevant MSDS or label in compliance with an undertaking and the date on which the notice referred to in subsection 16.1(3) of the Act was issued.

RN : 9187 Date : 2015-12-09

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the additional confidential ingredient “sodium sulfonate”.
  2. Disclose an LD50 (rat, oral) value of 2.23 g/kg for the confidential ingredient “zinc alkyldithiophosphate”.
  3. Disclose that an ingredient has been shown to cause mutagenic effects, in vitro, in the presence and absence of metabolic activation.
RN: 9191 Date: 2015-11-19

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the concentrations of the ingredients in the product.
RN: 9196 Date: 2015-12-22

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that acute ingestion of a hazardous ingredient has been shown to cause central nervous system effects and death in humans.
  2. Disclose that acute inhalation of an ingredient has been shown to cause respiratory tract irritation, central nervous system effects, acute pneumonitis, and edema in animals.
  3. Disclose that ingestion and inhalation of an ingredient have been shown to cause fetotoxicity and developmental toxicity in animals in the presence of maternal toxicity
  4. Disclose a LD50 (rabbit, dermal) value of 8.00 mL/kg for the ingredient “isopropanol”.
RN: 9204 Date: 2015-12-30

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause respiratory sensitization in humans.
  2. Disclose that an ingredient has been shown to cause fetotoxic effects in the presence of maternal toxicity in animals.
  3. Disclose the concentration of the ingredient “1-methoxy-2-proponol”.
  4. Disclose an ACGIH TLV–TWA value of 50 ppm and an ACGIH TLV–STEL value of 100 ppm for the ingredient “1-methoxy-2-proponol”.
RN: 9433 Date: 2015-12-09

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional ingredient, along with its CAS number, in the product.
  2. Disclose an LD50 (rat, oral) value of 2 000–5 000 mg/kg for the confidential ingredient “zinc alkyldithiophosphate”.
  3. Disclose that an ingredient has been shown to cause mutagenic effects, in vitro, in the presence and absence of metabolic activation.
RN: 9435 Date: 2015-11-23

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional ingredient, along with its CAS number and its concentration, or concentration range, in the product.
  2. Disclose the presence of an additional confidential ingredient, “substituted triazine”.
  3. Disclose an ACGIH TLV–TWA value of 200 ppm and an ACGIH TLV–STEL value of 250 ppm for the ingredient “methanol”.
  4. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D2A.
RN: 9436 Date: 2015-11-16

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional ingredient, along with its CAS number, in the product.
  2. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class B2.
RNs: 9437 and 9438 Date: 2015-12-22

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional confidential ingredient, “acrylic polymer”.
RN: 9442 Date: 2015-11-24

The claimant had been advised to amend certain aspects of the wording of the MSDS.

RN: 9443 Date: 2015-11-24

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose inhalation as a route of entry.
  2. Disclose the presence of an additional ingredient, along with its CAS number, in the product.
  3. Disclose that ingredients have been shown to cause reproductive toxicity in animals.
RN: 9445 Date: 2015-12-24

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of two additional confidential ingredients, “polyether polyol” and “monoalkylaryl alkoxylated”.
RN: 9453 Date: 2016-01-08

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional ingredient, along with its CAS number, in the product.
  2. Disclose an LD50 (rat, oral) value of 2.23 g/kg for the confidential ingredient “zinc alkyl dithiophosphate”.
  3. Disclose an LC50 (rat, aerosol, 4 hours) value of to 2.18 mg/L for the ingredient “distillates (petroleum), hydrotreated light naphthenic”.
  4. Disclose that an ingredient has been shown to cause mutagenic effects, in vitro, in the presence and absence of metabolic activation.
RNs: 9460 and 9461 Date: 2015-12-08

The claimant had been advised to amend certain aspects of the content of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to be an eye irritant.
RN: 9464 Date: 2016-01-08

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in classes B3 and E.
  2. Disclose the additional WHMIS pictogram for classes B and E, if WHMIS pictograms are shown on the MSDS.
  3. In relation to the first aid information shown on the MSDS for skin contact, disclose that medical attention must be obtained immediately.
  4. Disclose an ACGIH TWA value of 0.05 ppm and a STEL value of 0.15 ppm, with a skin notation, for the ingredient “bis(2-dimethlaminoethyl)ether”.
  5. Disclose the LD50 (rat, oral) values for the ingredients “bis(2-dimethylaminoethyl)ether” and “N,N-dimethylethanolamine” and the confidential ingredient “tertiary amines”.
  6. Disclose an LC50 (rat, vapour, 6 hours) value of 117 ppm for the ingredient “bis(2-dimethylanimoethyl)ether”.
  7. Disclose that an ingredient has been shown to cause fetotoxic effects in the presence of maternal toxicity in animals.
  8. Disclose an LD50 (rabbit, dermal) value of to 1.367 mL/kg for the ingredient “N,N-dimethylethanolamine”.
  9. Disclose an LC50 (rat, vapour, 4 hours) value of to 1 641 ppm for the ingredient “N,N-dimethylethanolamine”.
RN: 9466 Date: 2015-11-24

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose inhalation as a route of entry.
RN: 9468 Date: 2015-10-22

The claimant had been advised to amend certain aspects of the content of the MSDS and further advised to amend the MSDS as indicated below.

  1. Disclose the ACGIH skin notation for the ingredient “dipropylene glycol methyl ether”.
RN: 9470 Date: 2015-12-24

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of two additional confidential ingredients “ethoxylated polymer” and “ethoxylated amine”.
  2. Disclose explosion data — sensitivity to static discharge that is consistent with precautions to avoid sparks and sources of ignition.
  3. Disclose ingestion as an additional route of entry.
  4. Disclose that an ingredient has been shown to cause teratogenic effects in the presence of maternal toxicity in animals.
RN: 9473 Date: 2016-01-04

The claimant had been advised to amend certain aspects of the content and the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause skin sensitization in animals.
RNs: 9474 and 9475 Date: 2016-01-04

The claimant had been advised to amend certain aspects of the content and the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the concentration, or concentration range, for the confidential ingredients “styrene-acrylic copolymers” and “ethoxylated alkyl phosphates”.
  2. Disclose an LD50 (rat, oral) value of 1.26 g/kg for the ingredient “sodium dodecylbenzenesulfonate”.
RN: 9478 Date: 2015-12-21

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of the additional confidential ingredient “proprietary tall oil derivative”.
RN: 9480 Date: 2015-11-16

The claimant had been advised to amend certain aspects of the wording of the MSDS.

RN: 9481 Date: 2015-11-24

The claimant had been advised to amend certain aspects of the content of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause skin sensitization in animals.
  2. Disclose an LD50 (rat, oral) value of 9.0 mL/kg for the ingredient “fuels, diesel, No. 2”.
RN: 9482 Date: 2015-12-17

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose acceptable ACGIH TLV and ACGIH STEL exposure limits for the confidential ingredient “alkanolamine 1”.
  2. Disclose an LD50 (rat, oral) value of >500 mg/kg for the confidential ingredients “alkanolamine 1” and “alkanolamine 2”.
  3. Disclose an LD50 (rabbit, dermal) value of 1 000 mg/kg for the confidential ingredient “alkanolamine 2”.
RN: 9483 Date: 2015-12-21

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause skin sensitization in animals.
RNs: 9510, 9511, 9512, 9513, 9514 and 9515
Date: 2016-01-04

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9536 Date: 2015-12-14

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (rat, oral) value of 2.85 g/kg for the confidential ingredient “ethoxylated alcohols”.
  2. Disclose an LD50 (rat, oral) value of 2.46 mL/kg and an LD50 (rabbit, dermal) value of 2.38 mL/kg for the ingredient “2-ethyl hexanol”.
  3. Disclose that an ingredient has been shown to cause central nervous system effects, irritation of the respiratory tract and lung effects.
RN: 9550 Date: 2016-01-06

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (rat, oral) value of >500 mg/kg for the confidential ingredient “ethoxylated alcohols 2”.
  2. Disclose an LD50 (rabbit, dermal) value of >1 000 mg/kg for the confidential ingredient “ethoxylated alcohols 2”.
RN: 9561 Date: 2015-01-20

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional confidential ingredient, “cationic polymer”.
RN: 9568 Date: 2016-01-08

The claimant had been advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for skin contact, disclose a statement to the effect that contaminated clothing should be removed immediately.
RN: 9593 Date: 2015-12-22

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Add “oxides of carbon” and “oxides of nitrogen” to the list of hazardous decomposition products.
CLAIMS FOR WHICH THE SCREENING OFFICER ORDERED THE CLAIMANT TO COMPLY WITH THE APPLICABLE DISCLOSURE REQUIREMENTS

In the case of the following claims, either the claimant did not supply the screening officer with a signed undertaking or the screening officer was not satisfied that the claimant had taken the measures set out in the undertaking in the manner and within the period specified in it. Pursuant to subsection 17(1) of the Hazardous Materials Information Review Act, the screening officer ordered the claimant to comply with the requirements of the relevant legislation within 30 days from the expiry of the appeal period, except that the information in respect of which the claim for exemption was made does not have to be disclosed, and to provide a copy of the amended MSDS to the screening officer within 30 days of expiry of the appeal period.

Pursuant to paragraph 18(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that the screening officer ordered to be disclosed on the MSDS reviewed by the screening officer and the date of the order.

RNs: 9449 and 9450 Date: 2015-11-09

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Add “oxides of carbon” to the list of hazardous decomposition products.
RN: 9458 Date: 2015-11-30

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Add “oxides of carbon” and “oxides of sulphur” to the list of hazardous decomposition products.
CLAIMS FOR WHICH THE SCREENING OFFICER ISSUED THE DECISION THAT THE CLAIM FOR EXEMPTION WAS EITHER PARTIALLY VALID OR INVALID

In the case of the following claims, the screening officer issued the decision that the claims for exemption were partially valid.

Pursuant to section 18 of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that the screening officer ordered to be disclosed on an MSDS or a label pursuant to subsection 16(1) and information that has been disclosed on the relevant MSDS or label in compliance with an undertaking, and the dates on which the orders and notices referred to in subsection 16.1(3) of the Act were issued.

RN: 9184
Date of compliance undertaking: 2015-10-20

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional confidential ingredient, “monocyclic organic polymer”, and its concentration, or concentration range, in the product.
RN: 9214
Date of order: 2015-10-14

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional ingredient, along with its CAS registry number and its concentration, or concentration range, in the product.
Date of compliance undertaking: 2015-12-01

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (rat, oral) value for the confidential ingredient “xanthate derivative”.
  2. Disclose the concentrations, or concentration ranges, for the confidential ingredients “xanthate derivative” and “xanthate”.
  3. In relation to the first aid information shown on the MSDS for skin contact, disclose that medical attention must be obtained immediately.
  4. Disclose acceptable ACGIH TLV and OSHA PEL exposure limits for an ingredient.
  5. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class B3.
RNs: 9431 and 9432
Date of compliance undertaking: 2015-10-22

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (rat, oral) value of 6.5 mL/kg for the confidential ingredient “olefin sulfide”.
  2. Disclose that an ingredient has been shown to cause skin irritation.
  3. Disclose that an ingredient has been shown to cause skin sensitization in animals.
RN: 9438
Date of compliance undertaking: 2015-12-22

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional confidential ingredient, “acrylic polymer”.
RN: 9439
Date of compliance undertaking: 2015-11-19

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional confidential ingredient, “phenolic resin #2”.
  2. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D1A.
RN: 9444
Date of compliance undertaking: 2016-02-12

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D2B.
RN: 9447
Date of compliance undertaking: 2016-01-15

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional ingredient, along with its CAS registry number and its concentration, or concentration range, in the product.
RN: 9459
Date of compliance undertaking: 2016-01-21

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D1B.
  2. Disclose the additional WHMIS pictogram for class D1, if WHMIS pictograms are shown on the MSDS.
  3. Disclose an LD50 (rat, oral) value of 3.08 mL/kg for the ingredient “3-dimethylamino-N,N-dimethylpropionamide”.
  4. Disclose an LD50 (rabbit, dermal) value of 0.79 mL/kg for the ingredient “3-dimethylamino-N,N-dimethylpropionamide”.
RN: 9544
Date of compliance undertaking: 2015-12-11

The claimant had been advised to amend certain aspects of the content of the MSDS.

RN: 9562
Date of compliance undertaking: 2016-01-26

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional ingredient, along with its CAS registry number and its concentration, or concentration range, in the product.
RNs: 9566 and 9567
Date of compliance undertaking: 2016-01-08

The claimant had been advised to amend certain aspects of the content and the wording of the MSDS.

RN: 9578
Date of compliance undertaking: 2015-01-22

The claimant had been advised to amend certain aspects of the wording of the MSDS.

In the case of the following claims, the screening officer issued the decision that the claim for exemption was invalid.

Pursuant to section 18 of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that the screening officer ordered to be disclosed on an MSDS or label pursuant to subsection 16(1) and information that has been disclosed on the relevant MSDS or label in compliance with an undertaking, and the dates on which the orders and notices referred to in subsection 16.1(3) of the Act were issued.

RN: 9477
Date of compliance undertaking: 2015-12-21

The claimant had been advised to amend certain aspects of the wording of the MSDS.

RN: 9535
Date of compliance undertaking: 2015-12-21

The claimant had been advised to amend certain aspects of the wording of the MSDS.

CLAIMS FOR WHICH THE SCREENING OFFICER ISSUED A DECISION ON THE CLAIM FOR EXEMPTION BUT WHICH WERE DISCONTINUED PRIOR TO THE ISSUANCE OF EITHER A SIGNED UNDERTAKING OR SIGNED ORDERS

The screening officer has identified the following instances of non-compliance with the requirements of the relevant legislation.

RN: 9402
Date of statement of decision: 2015-07-09

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to be corrosive to the eyes and to the skin.
  2. Disclose the presence of an additional ingredient, along with its CAS registry number and its concentration, or concentration range, in the product.
  3. Disclose the concentrations of the ingredients in the product.
  4. Disclose that an ingredient has been shown to cause skin sensitization in animals.
RN: 9446
Date of statement of decision: 2015-11-30

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Add “oxides of carbon” and “oxides of nitrogen” to the list of hazardous decomposition products.

[13-1-o]

DEPARTMENT OF HEALTH

HAZARDOUS MATERIALS INFORMATION REVIEW ACT

Filing of claims for exemption

Pursuant to paragraph 12(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of the filing of the claims for exemption listed below.

In accordance with subsection 12(2) of the Hazardous Materials Information Review Act, affected parties, as defined, may make written representations to the screening officer with respect to the claim for exemption and the (material) safety data sheet ([M]SDS) or label to which it relates. Written representations must cite the appropriate registry number, state the reasons and evidence upon which the representations are based and be delivered within 30 days of the date of the publication of this notice in the Canada Gazette, Part I, to the screening officer at the following address: Workplace Hazardous Materials Bureau, 269 Laurier Avenue West, 4th Floor, Ottawa, Ontario K1A 0K9.

ROSSLYNN MILLER-LEE
Chief Screening Officer

On February 11, 2015, the Hazardous Products Act (HPA) was amended, and the Controlled Products Regulations (CPR) and the Ingredient Disclosure List were repealed and replaced with the new Hazardous Products Regulations (HPR). The revised legislation (HPA/HPR) is referred to as WHMIS 2015 and the former legislation (HPA/CPR) is referred to as WHMIS 1988. Transitional provisions allow compliance with either WHMIS 1988 or WHMIS 2015 for a specified period of time.

The claims listed below seek an exemption from the disclosure of employer confidential business information in respect of a controlled/hazardous product; such disclosure would otherwise be required under the provisions of the relevant legislation.

Claimant Product Identifier Subject of the Claim for Exemption Registry Number
Nalco Canada ULC NALCO® EC6697A C.i. and c. of one ingredient, information that could be used to identify a supplier of the controlled product 9784
Nalco Canada ULC SCAL06690A C.i. and c. of one ingredient, information that could be used to identify a supplier of the controlled product 9785

Note: C.i. = Chemical identity and c. = concentration

The claims listed below seek an exemption from the disclosure of supplier confidential business information in respect of a controlled/hazardous product; such disclosure would otherwise be required under the provisions of the relevant legislation.

Claimant Product Identifier Subject of the Claim for Exemption Registry Number
3M Canada Company 3M™ Blue Cream Hardener (Manufactured for 3M by Raichem) C. of one ingredient 9728
3M Canada Company 3M™ SANDBLAST FILLER 3 C. of four ingredients 9729
3M Canada Company 3M™ Scotch-Weld™ Core Splicer Adhesive EC-3500 B/A Part A C. of three ingredients 9730
3M Canada Company 3M™ Silicone Spray - CA C. of five ingredients 9731
3M Canada Company 3M™ Bondo® AutoBody Filler 310C C. of three ingredients 9732
3M Canada Company 3M™ Scotch-Weld™ Epoxy Adhesive 1838L Translucent Part A C. of two ingredients 9733
3M Canada Company 3M™ Scotch-Weld™ Structural Void Filling Compound EC-3460 HT/FST C. of five ingredients 9734
3M Canada Company 3M™ Dynatron® Dynalite Filler 492 C. of three ingredients 9735
3M Canada Company 3M™ Scotch-Weld™ Epoxy Adhesive DP420 Off-White, Part A C. of three ingredients 9736
3M Canada Company 3M™ Dynatron® Dynalite Filler 49 C. of three ingredients 9737
3M Canada Company 3M™ Dynatron® Dynalite Filler 496 C. of three ingredients 9738
3M Canada Company 3M™ Scotch-Weld™ Epoxy Adhesive DP420, Off-White (Part B) C. of one ingredient 9739
3M Canada Company 3M™ Scotch-Weld™ Polyurethane Sealant DP5001 Black, Part B C. of one ingredient 9740
3M Canada Company 3M™ Super 77™ Adhesive, Bulk C. of two ingredients 9741
3M Canada Company 3M™ Bondo Lightweight Body Filler 261C C. of three ingredients 9742
3M Canada Company 3M™ Bondo Lightweight Body Filler 262C C. of three ingredients 9743
3M Canada Company 3M™ Bondo Lightweight Body Filler 265C C. of three ingredients 9744
3M Canada Company 3M™ Rubber and Gasket Adhesive 4799 C. of five ingredients 9745
3M Canada Company 3M™ Hi-Strength 92 Bulk Adhesive, Clear C. of four ingredients 9746
3M Canada Company 3M™ 991 Thinner C. of one ingredient 9747
3M Canada Company 3M™ Scotch-Weld™ Fuel Resistant Coating EC-776 C. of five ingredients 9748
3M Canada Company 3M™ PLASTIC ADHESIVE EC-1458 C. of three ingredients 9749
3M Canada Company 3M™ Wind Epoxy Filler W3120, 10min Part B C. of two ingredients 9750
3M Canada Company 3M™ Scotch-Weld™ Structural Adhesive Primer EC-1593 C. of four ingredients 9751
3M Canada Company 3M™ FASTENER ADHESIVE 2510 ORANGE C. of six ingredients 9752
3M Canada Company 3M™ FASTENER ADHESIVE 2353 BLUE C. of four ingredients 9753
3M Canada Company 6045 SERIES STRUCTURAL ADHESIVE FILM C. of five ingredients 9754
3M Canada Company 3M™ Scotch-Weld™ Structural Void Filling Compound 3584 B/A: Part A C. of five ingredients 9755
3M Canada Company 3M™ Controltac™ Adhesive Remover R231 C. of six ingredients 9756
3M Canada Company 3M™ Stamark™ Low VOC Surface Preparation Adhesive SPA60 Cylinder Spray C. of two ingredients 9757
3M Canada Company 3M™ Stamark™ Low VOC Surface Preparation Adhesive SPA60 Fragrance Free (Bulk) C. of two ingredients 9758
3M Canada Company 3M™ 4430R CLEAR-PART A C. of three ingredients 9759
3M Canada Company 3M™ Scotch-Weld™ Urethane Adhesive DP620NS Black, Part B C. of two ingredients 9760
3M Canada Company 3M™ 4430R Clear – Part B C. of two ingredients 9761
3M Canada Company SUPER-CLEAR LENS CLEANING TOWELETTES C. of four ingredients 9762
3M Canada Company 3M™ Scotch-Weld™ Urethane Adhesive 620NS, Part B C. of two ingredients 9763
3M Canada Company 3M™ Scotch-Weld™ Epoxy Adhesive DP420NS Black, Part A C. of one ingredient 9764
3M Canada Company 3M™ Scotch-Weld™ Epoxy Adhesive 420NS Black, Part A C. of one ingredient 9765
3M Canada Company 3M™ Scotchkote Urethane Coating 362HT (Part B) C. of one ingredient 9766
3M Canada Company 3M™ Structural Bonding Tape 9270 with Components C. of two ingredients 9767
3M Canada Company 3M™ Bondo Red Cream Hardener 913C C. of two ingredients 9768
3M Canada Company 3M™ Scotchkote Epoxy Ceramic Surfacer FG 512, Blue (Part A) C. of three ingredients 9769
3M Canada Company Scotchrap™ Pipe Primer C. of two ingredients 9770
3M Canada Company 3M™ FIRE BARRIER WATERTIGHT SEALANT 3000 WT C. of one ingredient 9771
3M Canada Company StarStuk HNF 80 C. of one ingredient 9772
3M Canada Company 3M™ Scotch-Weld™ Epoxy Adhesive 420NS Black, Part B C. of one ingredient 9773
3M Canada Company 3M™ Scotch-Weld™ Epoxy Adhesive DP420NS Black, Part B C. of one ingredient 9774
3M Canada Company 3M™ Repositionable Spray Adhesive 75 C. of four ingredients 9775
3M Canada Company 3M™ Scotch-Weld™ Structural Void Filling Compound 3584 B/A: Part B C. of three ingredients 9776
3M Canada Company 3M™ Scotch-Weld™ Low Odor Acrylic Adhesive DP810NS Tan, Part B C. of three ingredients 9777
3M Canada Company 3M™ Scotch-Weld™ Low Odor Acrylic Adhesive 810NS Tan, Part B C. of three ingredients 9778
3M Canada Company 3M™ Ten Bond Contact Cement C. of five ingredients 9779
3M Canada Company SUPER 77 AEROSOL SPRAY LOW 25% VOC C. of four ingredients 9780
3M Canada Company 3M™ Scotch-Weld™ Low Odor Acrylic Adhesive DP810NS Tan, Part A C. of four ingredients 9781
3M Canada Company 3M™ Scotch-Weld™ Low Odor Acrylic Adhesive 810NS Tan, Part A C. of four ingredients 9782
Innospec Fuel Specialties DCI-80 C.i. and c. of three ingredients 9783
Novoset LLC Novoset 120-7A C.i. and c. of six ingredients 9786
Novoset LLC Novoset 250 C.i. and c. of six ingredients 9787
Afton Chemical Corporation Polartech® MA 3400 OF C.i. and c. of one ingredient, c. of two ingredients 9788
Baker Hughes Canada Company GasFlo G2 C.i. and c. of two ingredients 9789
Win Chemicals Ltd. EGM C.i. and c. of two ingredients 9790
Baker Hughes Canada Company TOLAD™ 9702 ADDITIVE C.i. of one ingredient 9791
Schlumberger Technology Corporation Corrosion Inhibitor A264A C.i. and c. of five ingredients, c. of four ingredients 9792
The Lubrizol Corporation SILSENSE® PE-100 SILICONE C.i. and c. of one ingredient, c. of one ingredient 9793
Trican Well Service Ltd. PFC-2 C.i. of two ingredients 9794
Afton Chemical Corporation HiTEC® 510A Performance Additive C.i. and c. of two ingredients, c. of three ingredients 9795
3M Canada Company 3M™ Impact Protection Adhesive Black C. of two ingredients 9796
3M Canada Company 3M™ Scotchkote Epoxy Ceramic Surfacer FG 512 (Part B) C. of five ingredients 9797
Air Products & Chemicals, Inc. ANCAMINE® 2334 Curing Agent C.i. of two ingredients 9798
Multi-Chem Production Chemicals Co. MC MX 5-3783 C.i. of one ingredient 9799
Multi-Chem Production Chemicals Co. HyStop™ MX 5-3920 C. of one ingredient 9800
Multi-Chem Production Chemicals Co. HyStop™ MXI 5-3912 C. of one ingredient 9801
Multi-Chem Production Chemicals Co. HyStop™ MX 5-3910 C. of one ingredient 9802
3M Canada Company 3M™ Bondo® Glazing & Spot Putty 650 C. of eight ingredients 9803
3M Canada Company 3M™ Bondo® Glazing & Spot Putty 907C C. of eight ingredients 9804
Materia Inc. Proxima® 2124 Resin C.i. of four ingredients, c. of six ingredients 9805
Specialty Intermediates, Inc. CI-429 C.i. and c. of one ingredient 9806
Specialty Intermediates, Inc. CI-430 C.i. and c. of two ingredients 9807
Akzo Nobel Surface Chemistry LLC BEROL ECO C.i. and c. of two ingredients 9808
Baker Hughes Canada Company LIFESPAN™ 3500 HEAVY OIL STABILIZER C.i. and c. of one ingredient, c.i of one ingredient, c. of three ingredients 9809
Specialty Intermediates, Inc. SIW-476 C.i. and c. of one ingredient 9810
3M Canada Company SCOTCHKOTE 323 P Patch Compound, Part B C. of five ingredients 9811
3M Canada Company 3M™ Wind Epoxy Filler W3120, 10min, Part A C. of three ingredients 9812
3M Canada Company 3M™ Scotchkote Urethane Coating 362HT, Grey (Part A) C. of two ingredients 9813
3M Canada Company SCOTCHKOTE 323 P Patch Compound, Part A C. of two ingredients 9814
Hydro Technologies (Canada) Inc. HY BRITE® MNA-1001 C.i. and c. of one ingredient 9815
Afton Chemical Corporation CUTSOL C.i. and c. of six ingredients 9816
3M Canada Company 3M™ Scotch-Weld™ Urethane Adhesive 620NS Black, Part A C. of two ingredients 9817
3M Canada Company 3M™ Industrial Plastic Adhesive 4475 C. of one ingredient 9818
3M Canada Company 3M™ Scotch-Weld™ Concrete Repair 600NS Gray, Part A C. of two ingredients 9819
3M Canada Company 3M™ Scotch-Weld™ Concrete Repair DP600NS Gray, Part A C. of two ingredients 9820
3M Canada Company 3M™ Scotch-Weld™ Urethane Adhesive DP620NS Black, Part A C. of two ingredients 9821
3M Canada Company 3M™ Scotch-Weld™ Epoxy Adhesive EC-2815 B/A FR, Part A C.i. and c. of one ingredient, c. of four ingredients 9822
3M Canada Company 3M™ Scotch-Weld™ Epoxy Adhesive EC-2815 B/A FR, Part B C. of three ingredients 9823
Nalco Canada ULC Torq Free™ HD C.i. and c. of one ingredient, c. of twelve ingredients 9824
Momentive Performance Materials Niax* catalyst A-440 C.i. and c. of two ingredients, c. of one ingredient 9825
Lamberti Canada Inc. HI 232C C.i. and c. of one ingredient 9826
Albemarle RT-235 C.i. of two ingredients 9827
Momentive Performance Materials Silblock* WMS C.i. and c. of three ingredients, c. of one ingredient 9828
3M Canada Company 3M™ THREAD SEALANT 4291 C. of three ingredients 9829
Afton Chemical Corporation HiTEC 6591N Fuel Additive C.i. and c. of one ingredient, c. of nine ingredients 9830
The Lubrizol Corporation Powerzol™ 9539 C.i. and c. of two ingredients 9831
Ingevity Corporation Enva Mul™ 2157 C.i. and c. of one ingredient 9832
Ingevity Corporation INDULIN® 209 (Export Only) C.i. and c. of one ingredient 9833
Afton Chemical Corporation HiTEC 521F Performance Additive C.i. and c. of one ingredient, c. of three ingredients 9834
The Lubrizol Corporation Powerzol™ 9543 C.i. and c. of three ingredients 9835
Canadian Energy Services EnerMul P-100 C.i. and c. of one ingredient 9836
Atotech Canada Ltd. EXPT ZINNI AL 454-1 C.i. of one ingredient 9837
Innospec Fuel Specialties LLC DCI-35 C.i. and c. of one ingredient 9838
Specialty Intermediates, Inc. SECURE CI-422 C.i. and c. of four ingredients 9839
Specialty Intermediates, Inc. SECURE SI-423 C.i. and c. of one ingredient 9840
Specialty Intermediates, Inc. SECURE DE-646 C.i. and c. of two ingredients 9841
Baker Hughes Canada Company FAW-30 C.i. and c. of one ingredient 9842
Baker Hughes Canada Company TRETOLITE™ RBW987 REVERSE BREAKER C.i. of two ingredients 9843
3M Canada Company 3M™ Neutral Cleaner Concentrate (Product No. 3, 3M™ Chemical Management Systems) C.i. and c. of two ingredients, c. of one ingredient 9844
Nalco Canada ULC 3D TRASAR 3DT408 C.i. and c. of one ingredient, c. of one ingredient 9845
Momentive Performance Materials SPUR+ 1015 LM Prepolymer Silyated Polyurethane Resin C.i. and c. of two ingredients, c. of one ingredient 9846
Home Hardware Stores Ltd. ACTIVOX SIDING PLUS C.i. and c. of one ingredient 9847
Home Hardware Stores Ltd. ACTIVOX SIDING PLUS ACTIVATOR C.i. and c. of two ingredients 9848
The Lubrizol Corporation LUBAD 1885 C.i. and c. of one ingredient 9849
Momentive Performance Materials Niax* silicone U-2000 Polyalkyleneoxidemethy Copolymer C.i. and c. of three ingredients 9850
Nalco Canada ULC CLAR17895A C.i. and c. of two ingredients 9851
Athlon Solutions LLC RPA-880 C.i. and c. of two ingredients 9852

Note: C.i. = Chemical identity and c. = concentration

[13-1-o]

DEPARTMENT OF INDUSTRY

OFFICE OF THE REGISTRAR GENERAL

Appointments

Name and position Order in Council
Blewett, Catherine 2016-111
  • Deputy Minister of Fisheries and Oceans
 
Boehm, Peter 2016-107
  • Associate Deputy Minister of Foreign Affairs and Deputy Minister for International Development to be styled Deputy Minister of International Development
 
Brown, Malcolm 2016-110
  • Deputy Minister of Public Safety and Emergency Preparedness to be styled Deputy Minister of Public Safety
 
Jacovella, Diane 2016-108
  • Associate Deputy Minister of Foreign Affairs
 
Jones, Dylan 2016-115
  • Deputy Minister of Western Economic Diversification
 
Keenan, Michael 2016-106
  • Deputy Minister of Transport
 
Laurendeau, Hélène 2016-109
  • Deputy Minister of Indian Affairs and Northern Development to be styled Deputy Minister of Indigenous and Northern Affairs
 
Lemay, Marie 2016-112
  • Deputy Minister of Public Works and Government Services to be styled Deputy Minister of Public Services and Procurement
 
Mithani, Siddika 2016-113
  • Public Health Agency of Canada
 
  • President
 
Tremblay, Jean-François 2016-105
  • Deputy Minister of Infrastructure
 
Volk, Coleen 2016-114
  • Associate Deputy Minister of Environment and Climate Change
 

March 14, 2016

DIANE BÉLANGER
Official Documents Registrar

[13-1-o]

DEPARTMENT OF TRANSPORT

Order Prohibiting the Development of an Aerodrome in the Cities of Mascouche and Terrebonne

Notice is hereby given that, on March 4, 2016, the Minister of Transport, pursuant to section 4.31 of the Aeronautics Act, issued an order to prohibit the development of an aerodrome within the limits of the City of Mascouche or the City of Terrebonne, in the Province of Quebec, as the Minister was of the opinion that such a development was not in the public interest. A person is therefore not to develop an aerodrome within the limits of the cities of Mascouche or Terrebonne unless the person meets the conditions of the Order, such as carries out the consultation process set out in the schedule to the Order.

A copy of this Order can be found on Transport Canada’s Web site at the following link: http://www.tc.gc.ca/eng/mediaroom/orders-directives-directions-letters-7497.html.

[13-1-o]

DEPARTMENT OF TRANSPORT

MARINE LIABILITY ACT

Ship-source Oil Pollution Fund

Pursuant to section 110 (see footnote 1) of the Marine Liability Act (the Act) and the Marine Liability Regulations made pursuant to paragraph 110(3)(b) (see footnote 2) of the Act, the maximum aggregate liability of the Ship-source Oil Pollution Fund in respect of any particular occurrence during the fiscal year commencing April 1, 2016, will be $168,656,700.

MARC GARNEAU, P.C., M.P.
Minister of Transport

[13-1-o]

DEPARTMENT OF TRANSPORT

MARINE LIABILITY ACT

Ship-source Oil Pollution Fund

Pursuant to section 113 (see footnote 3) of the Marine Liability Act (the Act) and the Marine Liability Regulations made pursuant to paragraph 113(3)(b) (see footnote 4) of the Act, the amount of the levy in respect of payments into the Ship-source Oil Pollution Fund required by subsection 112(2) (see footnote 5) of the Act would be 50.59 cents if the levy were to be imposed pursuant to subsection 114(1) (see footnote 6) of the Act during the fiscal year commencing April 1, 2016.

MARC GARNEAU, P.C., M.P.
Minister of Transport

[13-1-o]

DEPARTMENT OF VETERANS AFFAIRS

DEPARTMENT OF VETERANS AFFAIRS ACT

Notice of intent to amend the Veterans Burial Regulations, 2005

Notice is hereby given that Veterans Affairs Canada (VAC) intends to recommend to the Governor in Council that amendments be made to the Veterans Burial Regulations, 2005, pursuant to section 5 of the Department of Veterans Affairs Act.

Background

VAC provides funeral and burial assistance for eligible veterans through its Funeral and Burial Program. The Program provides financial assistance for funeral services, burial or cremation and military-style grave markers or inscription on private grave markers. The Last Post Fund (LPF) Corporation, a national, non-profit organization founded in 1909, administers the Program on behalf of the Department and in compliance with the Veterans Burial Regulations, 2005 (the Regulations).

When a veteran dies of a service-related disability, the veteran’s estate or family is eligible to receive financial assistance for funeral, burial and grave marking as a matter-of-right, up to the maximum amount set out in the Regulations. Assistance is also provided when the financial resources in a veteran’s estate are not sufficient to pay funeral, burial and grave marking expenses, as determined through a means test. The test assesses the value of the veteran’s estate and, if applicable, that of his or her survivor (i.e. the veteran’s spouse or common-law partner). Assistance is paid on a sliding scale based on need, and full or partial assistance is paid up to the maximum amount set out in the Regulations. In situations where there is a survivor, the Regulations allow the family home, a car and $12,015 to be exempt from the means-tested calculation.

In the 2015 Speech from the Throne, the Government of Canada committed to do more for veterans and their families, in gratitude for their service. The mandate letter of the Minister of Veterans Affairs and Associate Minister of National Defence included the responsibility of ensuring that all veterans receive a dignified burial.

Issue

The main issue that would be addressed through proposed regulatory amendments, which would help to enhance the services and benefits provided for eligible veterans under the Funeral and Burial Program, is the Survivor Estate Exemption Amount.

Survivor estate exemption amount

In 1995, the survivor estate exemption amount, prescribed in the Regulations, was $24,030 and subject to annual indexation. However, during that year the amount was reduced by half to $12,015 and annual indexation ceased. The amount has not been adjusted since that time. While the cost of living has steadily increased since 1995, and is likely to continue to increase, the real value of the survivor estate exemption amount has decreased, and will continue to decrease with each passing year. As a result, fewer applicants are qualifying for assistance to help defray the funeral, burial and grave marking expenses of their loved ones, leaving more and more surviving spouses or common-law partners, with already limited financial means, having to pay for these costs.

If the 1995 survivor estate exemption amount of $24,030 had continued to be indexed each year (using the Consumer Price Index), it would be $35,279 today.

Also, there is an issue with the name of the Regulations. The current name was introduced in 2005 when the Veterans Burial Regulations, 1995 and the Last Post Fund Regulations, 1995 were repealed and integrated into the current Veterans Burial Regulations, 2005.

The addition of “2005” to the title may have been reasonable when the Regulations were introduced to be consistent with the naming of the regulations that were being repealed at that time. However, having “2005” in the title is no longer necessary and may cause confusion. Some veterans, families and stakeholders may think that the Veterans Burial Regulations, 2005 are outdated, and this may cause them to search for an updated “2016” version. Also, adding the year that the Regulations were introduced to the title is not consistent with the naming conventions of other VAC regulations.

Objective

The main objective of these proposed regulatory amendments is to help ensure that a surviving spouse or common-law partner is better financially situated to move forward following the veteran’s death.

A secondary objective of the proposed regulatory amendments is to clarify and simplify the title of the Regulations.

Description and rationale

The following changes to the Regulations are proposed:

Survivor estate exemption amount

The proposed regulatory amendments would increase the survivor’s estate exemption amount from $12,015 to $35,279, and would provide annual indexation to this amount, to begin the year after implementation of the regulatory changes.

As an increased amount of money would be exempt from the means-tested calculations, the spouse or common-law partner would be able to retain more financial resources following the veteran’s death and make a more gradual transition to a new financial situation (i.e. loss of the veteran’s income). The amendments would also enable some survivors, who would have been denied assistance with the lower survivor estate exemption amount, to now qualify for funeral and burial assistance. It is hoped that these changes would help to alleviate some of the financial pressures and worries that the survivors may be facing at an already difficult and emotional time in their lives.

Also, to provide clarity and simplicity, the amendments would remove “2005” from the title of the Regulations.

These proposed regulatory amendments would create no costs or administrative burden for veterans, their survivors or businesses.

Implementation, enforcement and service standards

It is being proposed that these regulatory changes would come into force on October 1, 2016. There would be no impact to the delivery of the Funeral and Burial Program as a result of these regulatory changes. The existing service delivery infrastructure would continue to be utilized. No additional staff or administrative funding would be required by VAC or the LPF Corporation to implement these regulatory changes. The Program’s terms and conditions, policies, directives, business processes and application forms would be revised to reflect the changes. VAC and LPF staff would be trained on these updates. Ongoing communications with LPF staff, as the third party provider, would be an integral component for the successful implementation of the changes.

Communication materials would be created to advise key stakeholders, veterans and their families of the changes to the Funeral and Burial Program. Changes would also be communicated through the LPF Corporation’s Web site and publications.

Upon the expected date of the coming into force of these regulatory changes, namely October 1, 2016, applications would continue to be processed by the LPF Corporation, which would administer the Funeral and Burial Program using the revised Regulations and policies.

These regulatory changes would not have an impact on legislative or regulatory compliance. In its ongoing efforts to support program performance, VAC currently has a performance measurement strategy in place for the Funeral and Burial Program. Ongoing reporting would ensure data is accurately captured to portray the Program’s performance, support future evaluations and help the Program in achieving its ultimate outcome: that Canadian veterans and those who died in service be honored and the memory of their achievements and sacrifices be preserved.

In addition, VAC’s Audit and Evaluation Division conducts annual audits and evaluations of VAC programs. Results are published regularly on VAC’s external Web site.

VAC also has established specific service standards for the Funeral and Burial Program, including providing timely decisions to applicants for funeral and burial assistance. The regulatory changes would have no impact on these service standards, allowing them to be maintained at the current average times.

Public comment period

Interested parties who wish to comment on the proposed amendments are invited to submit their comments, within 30 days after publication of this notice in the Canada Gazette, Part I, to Katherine Morrow, Manager, Cabinet Business Unit, Policy Division, Veterans Affairs Canada, by mail (P.O. Box 7700, Charlottetown, Prince Edward Island C1A 8M9), by telephone (902-370-4638) or by email (Katherine.Morrow@vac-acc.gc.ca).

[13-1-o]

BANK OF CANADA

Statement of financial position as at February 29, 2016

(Millions of dollars) Unaudited

ASSETS

Cash and foreign deposits

 

10.9

Loans and receivables

Securities purchased under resale agreements

6,098.9

 

Advances to members of the Canadian Payments Association

 

Advances to governments

 

Other receivables

6.4

 
   

6,105.3

Investments

Treasury bills of Canada

15,725.1

 

Government of Canada bonds

76,130.3

 

Other investments

402.1

 
   

92,257.5

Property and equipment

 

447.1

Intangible assets

 

36.8

Other assets

 

183.8

 

99,041.5


LIABILITIES AND EQUITY

Bank notes in circulation

 

72,845.3

Deposits

Government of Canada

22,895.6

 

Members of the Canadian Payments Association

436.9

 

Other deposits

1,630.9

 
   

24,963.4

Other liabilities

Securities sold under repurchase agreements

 

Other liabilities

738.3

 
   

738.3

   

98,547.0

Equity

Share capital

5.0

 

Statutory and special reserves

125.0

 

Available-for-sale reserve

364.5

 
   

494.5

99,041.5

I declare that the foregoing return is correct according to the books of the Bank.

Ottawa, March 15, 2016

CARMEN VIERULA
Chief Financial Officer and Chief Accountant

I declare that the foregoing return is to the best of my knowledge and belief correct, and shows truly and clearly the financial position of the Bank, as required by section 29 of the Bank of Canada Act.

Ottawa, March 15, 2016

CAROLYN A. WILKINS
Senior Deputy Governor

[13-1-o]